(Press-News.org) Sophia Antipolis, France – 7 April 2024: The first EU-wide trial aiming to improve the care of elderly atrial fibrillation patients with additional chronic health conditions has enrolled its first patient. The EU-funded EHRA-PATHS study is coordinated by the European Society of Cardiology (ESC) and the European Heart Rhythm Association (EHRA) of the ESC.
Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million individuals worldwide.1 The likelihood of developing the condition increases with age and the number of other conditions such as high blood pressure, diabetes, heart failure, coronary artery disease, kidney disease, obesity, and obstructive sleep apnoea. Patients with atrial fibrillation have an average of five co-existing conditions,2 and these comorbidities negatively impact survival.3 In addition, three-quarters of atrial fibrillation patients take at least five medications.4
The EHRA-PATHS trial is evaluating how comorbidities in elderly patients with atrial fibrillation are currently managed. It will then examine whether newly developed care pathways lead to better identification and management of comorbidities compared to the standard of care.
Principal investigator Professor Isabelle Van Gelder said: “Health care systems focus on one disease at a time. This increases the risks of underdiagnosing other conditions and of adverse interactions between medications for different diseases – a scenario which is detrimental to patients and costly for health services. EHRA-PATHS will test out new care pathways that provide holistic management for elderly patients with atrial fibrillation by also addressing their other chronic conditions. The trial will be conducted in 14 countries, providing the opportunity to address differences in health care systems throughout Europe.”
EHRA-PATHS investigators have developed novel care pathways for 22 common comorbidities and risk factors experienced by patients with atrial fibrillation, of which 12 will be evaluated in this trial: hypertension, hyperlipidaemia, heart failure, overweight/obesity, renal insufficiency, smoking, diabetes, coronary heart disease, valvular disease, physical activity, chronic obstructive pulmonary disease/asthma, and alcohol consumption. Each care pathway will assist health care professionals to check for or exclude whether a given comorbidity or risk factor is present, in order to guide its further evaluation and effective management. All 12 care pathways have been incorporated into a software tool to enable health care personnel to evaluate atrial fibrillation patients in a systematic and comprehensive way.
The clinical trial is set to recruit patients aged 65 years and older with newly diagnosed atrial fibrillation from 68 hospitals in Austria, Belgium, Bulgaria, Croatia, France, Germany, Greece, Italy, the Netherlands, Poland, Portugal, Spain, Sweden, and the United Kingdom. Part one of the study will examine the current management (assessment and treatment) of risk factors and comorbidities in approximately 1,300 patients to establish a baseline picture. Part two will be a randomised controlled trial in 1,080 patients to assess whether the implementation of novel systematic care pathways using a dedicated software tool improves the management of comorbidities associated with atrial fibrillation compared with the standard of care.
The primary endpoint is the number of risk factors and comorbidities that are identified and for which treatment is initiated during baseline mapping (part one) and at the end of the randomised controlled trial (part two). The secondary endpoints include atrial fibrillation symptom burden; ablation; hospitalisations for stroke, heart failure, and severe bleeding; mortality; quality of life; patient and health care professional satisfaction; referrals to other disciplines; and cost-effectiveness.
Principal investigator Professor Michiel Rienstra said: “We hope the trial will show that by using a systematic approach with an easy-to-use software tool, more comorbidities will be identified and treated in patients with atrial fibrillation compared to usual practice. In addition, we expect that better comorbidity management will consequently improve symptoms and quality of life, while reducing health care costs. Data from the trial will be used to pursue regulatory approval of the software so that it can be made available to health care professionals around Europe.”
Stay tuned for an EHRA-PATHS session at the EHRA Congress for an in-depth examination of the complex relationship between atrial fibrillation and other health conditions.5 Including insights from patients on their perception of atrial fibrillation care.
ENDS
Authors: ESC Press Office
Tel: +33 (0)489 872 075
Email: press@escardio.org
Follow us on X @ESCardioNews
Notes to editor
EHRA-PATHS has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945260.
References and notes
1Hindricks G, Potpara T, Nikolaos Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.
2Chamberlain AM, Alonso A, Gersh BJ, et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. Am Heart J. 2017;185:74–84.
3Jani BD, Nicholl BI, McQueenie R, et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace. 2018;20:f329–f336.
4Shaikh F, Pasch LB, Newton PJ, et al. Addressing multimorbidity and polypharmacy in individuals with atrial fibrillation. Curr Cardiol Rep. 2018;20:32.
5EHRA-PATHS will be discussed during the session ‘Comorbidity management in patients presenting with atrial fibrillation – the EHRA-PATHS Project’ which takes place on 7 April 2024 at 17:15 CEST in Room 4.
About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve patients’ quality of life and reduce sudden cardiac death by limiting the impact of heart rhythm disturbances.
About the EHRA Congress #EHRA2024
EHRA 2024 is the annual congress of the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC).
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists about registration for EHRA 2024
EHRA 2024 will be held 7 to 9 April at the CityCube Berlin, Germany, and online. Explore the scientific programme.
Free registration applies to accredited press.
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
The ESC Press Office decision is final regarding all press registration requests.
END
Trial to improve management of common heart rhythm disorder enrols first patient
2024-04-07
ELSE PRESS RELEASES FROM THIS DATE:
Electronic sock detects unhealthy walking style
2024-04-07
Berlin, Germany – 7 April 2024: An electronic sock that detects an unhealthy walking style linked with diabetes and poor circulation shows promise for preventing foot ulcers and amputation. The novel research is set to benefit the many patients with diabetes who have clogged arteries in the legs and is presented for the first time at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1
Study author Dr. Ki Hong Lee of Chonnam National University Hospital, Gwangju, Republic of Korea said: “Diabetes can affect the way people walk, also known as their gait. Patients with diabetes tend to put pressure ...
Stopping aspirin one month after coronary stenting procedures significantly reduces bleeding complications in heart attack patients
2024-04-07
Withdrawing aspirin one month after percutaneous coronary intervention (PCI) in high-risk heart patients and keeping them on ticagrelor alone safely improves outcomes and reduces major bleeding by more than half when compared to patients taking aspirin and ticagrelor combined (also known as dual antiplatelet therapy or DAPT), which is the current standard of care.
These are the results from the ULTIMATE-DAPT study announced during a late-breaking trial presentation at the American College of Cardiology Scientific ...
Short-term incentives for exercise can lead to sustained increases in activity
2024-04-07
Short-term incentives for exercise can lead to sustained increases in activity
NIH-supported study shows certain perks can spur long-term behavior change in adults with cardiovascular disease risks
Adults with heart disease risks who received daily reminders or incentives to become more active increased their daily steps by more than 1,500 after a year, and many were still sticking with their new habit six months later, according to a study supported by the National Institutes of Health that published in Circulation. ...
Successful “first in human” clinical trial of pioneering guidance for heart bypass surgery
2024-04-07
A new approach to the guidance, planning and conduct of heart bypass surgery has been successfully tested on patients for the first time in a clinical trial coordinated by a research team at University of Galway.
The FAST TRACK CABG study, overseen by the University’s CORRIB Research Centre for Advanced Imaging and Core Lab, has seen heart surgeons plan and carry out coronary artery bypass grafting (CABG), based solely on non-invasive cardiac-CT scan images, with HeartFlow’s AI-powered blood flow analysis of the patient’s coronary arteries.
The research was published today in the European Heart Journal and is available at https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehae199
The ...
Influenza vaccine immune response in patients with high-risk cardiovascular disease
2024-04-07
About The Study: High-dose influenza vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED randomized clinical trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations.
Authors: Scott D. Solomon, M.D., of Brigham and Women’s Hospital and Harvard Medical ...
Plozasiran (ARO-APOC3) for severe hypertriglyceridemia
2024-04-07
About The Study: This randomized clinical trial demonstrates the potential clinical utility of plozasiran, an investigational APOC3-targeted small interfering–RNA drug, to reduce triglyceride level in patients with severe hypertriglyceridemia. Additional studies will be required to determine whether plozasiran favorably modulates the risk of severe hypertriglyceridemia-associated complications.
Authors: Daniel Gaudet, M.D., Ph.D., of the Université de Montréal, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0959)
Editor’s ...
Experimental drug could further reduce lipids in the blood in high-risk patients
2024-04-07
Hypertriglyceridemia, or high levels of lipids (fats) in the blood, increases the risk of heart attack, stroke and acute pancreatitis. Currently available medications, including statins, ezetimibe, fibrates and prescription omega 3 fatty acids, typically lower triglyceride levels by anywhere from below 10% to up to 40%. These therapies help, but they are not enough to prevent cardiovascular events in everyone.
An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled ...
New evidence links passive smoking with dangerous heart rhythm disorder
2024-04-07
Berlin, Germany – 7 April 2024: Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened.
“The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial ...
Oral vaccine for UTI is potential alternative to antibiotics, finds 9-year study
2024-04-07
Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research.
Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris.
They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published ...
Antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures
2024-04-06
About The Study: This systematic review and meta-analysis including data on 1.1 million cases of infective endocarditis found that antibiotic prophylaxis was associated with a reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk but not in those at moderate or low/unknown risk. Currently, there is insufficient data to support any benefit of antibiotic prophylaxis in individuals at moderate risk.
Authors: Federica Turati, Ph.D., of the ...